• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

James D. Griffin, MD


  • Wu H, Wang W, Liu F, Weisberg EL, Tian B, Chen Y, Li B, Wang A, Wang B, Zhao Z, McMillin DW, Hu C, Li H, Wang J, Liang Y, Buhrlage SJ, Liang J, Liu J, Yang G, Brown JR, Treon SP, Mitsiades CS, Griffin JD, Liu Q, Gray NS.Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.ACS Chem Biol. 2014 May 16(5):1086-91.
  • Adamia S, Bar-Natan M, Haibe-Kains B, Pilarski PM, Bach C, Pevzner S, Calimeri T, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Galinsky I, Mathews S, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Tenen DG, Stone RM, Griffin JD.NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.Blood. 2014 May 1(18):2816-25.
  • Adamia S, Haibe-Kains B, Pilarski PM, Bar-Natan M, Pevzner S, Avet-Loiseau H, Lode L, Verselis S, Fox EA, Burke J, Galinsky I, Dagogo-Jack I, Wadleigh M, Steensma DP, Motyckova G, Deangelo DJ, Quackenbush J, Stone R, Griffin JD.A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.Clin Cancer Res. 2014 Mar 1;20(5):1135-45.
  • Kim HG, Tan L, Weisberg EL, Liu F, Canning P, Choi HG, Ezell SA, Wu H, Zhao Z, Wang J, Mandinova A, Griffin JD, Bullock AN, Liu Q, Lee SW, Gray NS.Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor.ACS Chem Biol. 2013 Oct 18;8(10):2145-50.
  • Toms AV, Deshpande A, McNally R, Jeong Y, Rogers JM, Kim CU, Gruner SM, Ficarro SB, Marto JA, Sattler M, Griffin JD, Eck MJ.Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases.Nat Struct Mol Biol. 2013 Oct;20(10):1221-3.
  • Adamia S, Pilarski PM, Bar-Natan M, Stone RM, Griffin JD.Alternative splicing in chronic myeloid leukemia (CML): a novel therapeutic target?.Curr Cancer Drug Targets. 2013 Sep;13(7):735-48.
  • Liu F, Zhang X, Weisberg E, Chen S, Hur W, Wu H, Zhao Z, Wang W, Mao M, Cai C, Simon NI, Sanda T, Wang J, Look AT, Griffin JD, Balk SP, Liu Q, Gray NS.Discovery of a Selective Irreversible BMX Inhibitor for Prostate Cancer.ACS Chem Biol. 2013 Apr 17.
  • Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ.Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib - a retrospective chart review analysis.Curr Med Res Opin. 2013 Apr 8.
  • Weisberg E, Liu Q, Zhang X, Nelson E, Sattler M, Liu F, Nicolais M, Zhang J, Mitsiades C, Smith RW, Stone R, Galinsky I, Nonami A, Griffin JD, Gray N.Selective Akt inhibitors synergize with tyrosine kinase inhibitors and effectively override stroma-associated cytoprotection of mutant FLT3-positive AML cells.PLoS ONE. 2013;8(2):e56473.
  • Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais M, Griffin JD, Stone RM, Kung AL, Frank DA.The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations.Genes Cancer. 2012 Jul;3(7-8):503-11.
  • Choi HG, Zhang J, Weisberg E, Griffin JD, Sim T, Gray NS.Development of 'DFG-out' inhibitors of gatekeeper mutant kinases.Bioorg Med Chem Lett. 2012 Aug 15;22(16):5297-302.
  • Guérin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD.A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.Curr Med Res Opin. 2012 Jul;28(7):1155-62.
  • Deng X, Zhou W, Weisberg E, Wang J, Zhang J, Sasaki T, Nelson E, Griffin JD, Jänne PA, Gray NS.An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit.Bioorg Med Chem Lett. 2012 Jul 15;22(14):4579-84.
  • Weisberg E, Azab AK, Manley PW, Kung AL, Christie AL, Bronson R, Ghobrial IM, Griffin JD.Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.Leukemia. 2012 May;26(5):985-90.
  • Deshpande A, Reddy MM, Schade GO, Ray A, Chowdary TK, Griffin JD, Sattler M.Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms.Leukemia. 2012 Apr;26(4):708-15.
  • Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, Griffin JD, Gray N.Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors, and JAK inhibitors.Leukemia. 2012 Apr 3.
  • Reddy MM, Fernandes MS, Deshpande A, Weisberg E, Inguilizian HV, Abdel-Wahab O, Kung AL, Levine RL, Griffin JD, Sattler M.The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity.Leukemia. 2012 Mar;26(3):481-9.
  • Weisberg E, Ray A, Nelson E, Adamia S, Barrett R, Sattler M, Zhang C, Daley JF, Frank D, Fox E, Griffin JD.Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells.PLoS ONE. 2011;6(9):e25351.
  • Nelson EA, Walker SR, Weisberg E, Bar-Natan M, Barrett R, Gashin LB, Terrell S, Klitgaard JL, Santo L, Addorio MR, Ebert BL, Griffin JD, Frank DA.The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors.Blood. 2011 Mar 24;117(12):3421-9.
  • Chen J, Kesari S, Rooney C, Strack PR, Chen J, Shen H, Wu L, Griffin JD.Inhibition of Notch Signaling Blocks Growth of Glioblastoma Cell Lines and Tumor Neurospheres.Genes Cancer. 2010 Aug 1;1(8):822-835.
  • Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD.Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.Curr Med Res Opin. 2010 Dec;26(12):2861-9.
  • Fernandes MS, Reddy MM, Croteau NJ, Walz C, Weisbach H, Podar K, Band H, Carroll M, Reiter A, Larson RA, Salgia R, Griffin JD, Sattler M.Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.J Biol Chem. 2010 Oct 15;285(42):32596-605.
  • Weisberg E, Choi HG, Barrett R, Zhou W, Zhang J, Ray A, Nelson EA, Jiang J, Moreno D, Stone R, Galinsky I, Fox E, Adamia S, Kung AL, Gray NS, Griffin JD.Discovery and characterization of novel mutant FLT3 kinase inhibitors.Mol Cancer Ther. 2010 Sep;9(9):2468-77.
  • Weisberg E, Choi HG, Ray A, Barrett R, Zhang J, Sim T, Zhou W, Seeliger M, Cameron M, Azam M, Fletcher JA, Debiec-Rychter M, Mayeda M, Moreno D, Kung AL, Janne PA, Khosravi-Far R, Melo JV, Manley P, Adamia S, Wu C, Gray N, Griffin JD.Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.Blood. 2010 May 27;115(21):4206-16.
  • Zhang Y, Askenazi M, Jiang J, Luckey CJ, Griffin JD, Marto JA.A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia.Mol Cell Proteomics. 2010 May;9(5):780-90.
  • Jin B, Shen H, Lin S, Li JL, Chen Z, Griffin JD, Wu L.The maml1 co-activator regulates constitutive NF-{kappa}B signaling and cell survival.J Biol Chem. 2010 May 7;285(19):14356-65.
  • McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS.Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.Nat Med. 2010 Apr;16(4):483-9.
  • Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM.Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):252-7.
  • Sattler M, Griffin JD.JAK2 gets histone H3 rolling.Cancer Cell. 2009 Nov 6;16(5):365-6. Review.
  • Fernandes MS, Reddy MM, Gonneville JR, DeRoo SC, Podar K, Griffin JD, Weinstock DM, Sattler M.BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair.Blood. 2009 Aug 27;114(9):1813-9.
  • Weisberg E,Barrett R,Liu Q,Stone R,Gray N,Griffin JD.FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.Drug Resist Updat. 2009 Jun;12(3):81-9. Review.
  • Smith KA,Griffin JD.Following the cytokine signaling pathway to leukemogenesis: a chronology.J Clin Invest. 2008 Nov;118(11):3564-73. Review.
  • Weisberg E,Roesel J,Bold G,Furet P,Jiang J,Cools J,Wright RD,Nelson E,Barrett R,Ray A,Moreno D,Hall-Meyers E,Stone R,Galinsky I,Fox E,Gilliland G,Daley JF,Lazo-Kallanian S,Kung AL,Griffin JD.Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.Blood. 2008 Dec 15;112(13):5161-70.
  • Weisberg E, Wright RD, McMillin DW, Mitsiades C, Ray A, Barrett R, Adamia S, Stone R, Galinsky I, Kung AL, Griffin JD.Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.Mol Cancer Ther. 2008 May;7(5):1121-9.
  • Loriaux MM, Levine RL, Tyner JW, Frohling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, Stone RM, Lee B, Meyerson M, Heinrich MC, Deininger MW, Gilliland DG, Druker BJ.High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.Blood. 2008 May 1;111(9):4788-96.
  • Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M.The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.Blood. 2008 Apr 1;111(7):3751-9.
  • Weisberg E, Banerji L, Wright RD, Barrett R, Ray A, Moreno D, Catley L, Jiang J, Hall-Meyers E, Sauveur-Michel M, Stone R, Galinsky I, Fox E, Kung AL, Griffin JD.Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.Blood. 2008 Apr 1;111(7):3723-34.
  • Frohling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Dohner H, Dohner K, Ebert BL, Teckie S, Golub TR, Jiang J, Schittenhelm MM, Lee BH, Griffin JD, Stone RM, Heinrich MC, Deininger MW, Druker BJ, Gilliland DG.Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.Cancer Cell. 2007 Dec;12(6):501-13.
  • Griffin JE.Resuscitation decisions: yes, but who is in charge?.BMJ. 2007 Nov 17;335(7628):1008.
  • Wu L, Maillard I, Nakamura M, Pear WS, Griffin JD.The transcriptional coactivator Maml1 is required for Notch2-mediated marginal zone B-cell development.Blood. 2007 Nov 15;110(10):3618-23.
  • Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A, Zawel L, Tran M, Cools J, Gilliland G, Mitsiades C, McMillin DW, Jiang J, Hall-Meyers E, Griffin JD.Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells.Mol Cancer Ther. 2007 Jul;6(7):1951-61.
  • Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD.Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.Nat Rev Cancer. 2007 May;7(5):345-56. Review.
  • Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD.Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.Blood. 2007 Jun 1;109(11):5011-5.
  • Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, Dabora SL, Griffin JD, Kwiatkowski DJ.PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR.J Clin Invest. 2007 Mar;117(3):730-8.
  • Chen J, Jette C, Kanki JP, Aster JC, Look AT, Griffin JD.NOTCH1-induced T-cell leukemia in transgenic zebrafish.Leukemia. 2007 Mar;21(3):462-71.
  • Weisberg E, Wright RD, Jiang J, Ray A, Moreno D, Manley PW, Fabbro D, Hall-Meyers E, Catley L, Podar K, Kung AL, Griffin JD.Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.Gastroenterology. 2006 Dec;131(6):1734-42.
  • Weisberg E, Catley L, Wright RD, Moreno D, Banerji L, Ray A, Manley PW, Mestan J, Fabbro D, Jiang J, Hall-Meyers E, Callahan L, DellaGatta JL, Kung AL, Griffin JD.Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.Blood. 2007 Mar 1;109(5):2112-20.
  • Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG.Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.N Engl J Med. 2006 Jun 15;354(24):2542-51.
  • Weisberg E, Manley P, Mestan J, Cowan-Jacob S, Ray A, Griffin JD.AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.Br J Cancer. 2006 Jun 19;94(12):1765-9. Review.
  • Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K, Griffin JD, Sattler M.Activated Jak2 with the V617F point mutation promotes G1/S phase transition.J Biol Chem. 2006 Jun 30;281(26):18177-83.
  • Shen H, McElhinny AS, Cao Y, Gao P, Liu J, Bronson R, Griffin JD, Wu L.The Notch coactivator, MAML1, functions as a novel coactivator for MEF2C-mediated transcription and is required for normal myogenesis.Genes Dev. 2006 Mar 15;20(6):675-88.
  • Sattler M, Walz C, Crowley BJ, Lengfelder E, Jnne PA, Rogers AM, Kuang Y, Distel RJ, Reiter A, Griffin JD.A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples.Blood. 2006 Feb 1;107(3):1237-8.
  • Jiang J, Greulich H, Jnne PA, Sellers WR, Meyerson M, Griffin JD.Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.Cancer Res. 2005 Oct 1;65(19):8968-74.
  • Lee BH, Williams IR, Anastasiadou E, Boulton CL, Joseph SW, Amaral SM, Curley DP, Duclos N, Huntly BJ, Fabbro D, Griffin JD, Gilliland DG.FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.Oncogene. 2005 Nov 24;24(53):7882-92.
  • Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Moore S, Huntly BJ, Fabbro D, Anderson KC, Griffin JD, Gilliland DG.FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.Oncogene. 2005 Dec 15;24(56):8259-67.
  • Levine RL, Loriaux M, Huntly BJ, Loh ML, Beran M, Stoffregen E, Berger R, Clark JJ, Willis SG, Nguyen KT, Flores NJ, Estey E, Gattermann N, Armstrong S, Look AT, Griffin JD, Bernard OA, Heinrich MC, Gilliland DG, Druker B, Deininger MW.The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.Blood. 2005 Nov 15;106(10):3377-9.
  • Stover EH, Chen J, Lee BH, Cools J, McDowell E, Adelsperger J, Cullen D, Coburn A, Moore SA, Okabe R, Fabbro D, Manley PW, Griffin JD, Gilliland DG.The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.Blood. 2005 Nov 1;106(9):3206-13.
  • Golemovic M, Verstovsek S, Giles F, Cortes J, Manshouri T, Manley PW, Mestan J, Dugan M, Alland L, Griffin JD, Arlinghaus RB, Sun T, Kantarjian H, Beran M.AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.Clin Cancer Res. 2005 Jul 1;11(13):4941-7.
  • Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, Gilliland DG.Activation mutations of human c-KIT resistant to imatinib are sensitive to the tyrosine kinase inhibitor PKC412.Blood. 2005 Jul 15;106(2):721-4.
  • Wu L, Liu J, Gao P, Nakamura M, Cao Y, Shen H, Griffin JD.Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation.EMBO J. 2005 Jul 6;24(13):2391-402.
  • Griffin JM, Amand MS, Demetri GD.Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors.Clin J Oncol Nurs. 2005 Apr;9(2):161-9.
  • Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Frohling S, Dohner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG.Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Cancer Cell. 2005 Apr;7(4):387-97.
  • Mayerhofer M, Aichberger KJ, Florian S, Krauth MT, Hauswirth AW, Derdak S, Sperr WR, Esterbauer H, Wagner O, Marosi C, Pickl WF, Deininger M, Weisberg E, Druker BJ, Griffin JD, Sillaber C, Valent P.Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.FASEB J. 2005 Jun;19(8):960-2.
  • Griffin JD.Interaction maps for kinase inhibitors.Nat Biotechnol. 2005 Mar;23(3):308-9.
  • Okuda K, Oda A, Sato Y, Nakayama A, Fujita H, Sonoda Y, Griffin JD.Signal transduction and cellular functions of the TEL/ARG oncoprotein.Leukemia. 2005 Apr;19(4):603-10.
  • Weisberg E, Manley PW, Breitenstein W, Brggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Mohammed A, Neuberg D, Wright RD, Gilliland DG, Griffin JD.Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.Cancer Cell. 2005 Feb;7(2):129-41.
  • Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD.Acute myeloid leukemia patients with an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412.Blood. 2005 Jan 1;105(1):54-60.
  • Kim JH, Chu SC, Gramlich JL, Pride YB, Babendreier E, Chauhan D, Salgia R, Podar K, Griffin JD, Sattler M.Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species.Blood. 2005 Feb 15;105(4):1717-23.
  • Cools J, Mentens N, Furet P, Fabbro D, Clark JJ, Griffin JD, Marynen P, Gilliland DG.Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.Cancer Res. 2004 Sep 15;64(18):6385-9.
  • Lin B, Catley L, LeBlanc R, Mitsiades C, Burger R, Tai YT, Podar K, Wartmann M, Chauhan D, Griffin JD, Anderson KC.Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.Blood. 2005 Jan 1;105(1):350-7.
  • Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM.After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies.Blood. 2005 Jan 1;105(1):22-30.
  • Chen J, Wall NR, Kocher K, Duclos N, Fabbro D, Neuberg D, Griffin JD, Shi Y, Gilliland DG.Stable expression of small interfering RNA sensitizes TEL-PDGFbetaR to inhibition with imatinib or rapamycin.J Clin Invest. 2004 Jun;113(12):1784-91.
  • Gu TL, Tothova Z, Scheijen B, Griffin JD, Gilliland DG, Sternberg DW.The NPM-ALK Fusion Kinase of Anaplastic Large Cell Lymphoma Regulates Survival and Proliferative Signaling Through Modulation of FOXO3a.Blood. 2004 Jun 15;103(12):4622-9.
  • Wu L, Kobayashi K, Sun T, Gao P, Liu J, Nakamura M, Weisberg E, Mukhopadhyay NK, Griffin JD.Cloning and functional characterization of the murine mastermind-like 1 (Maml1) gene.Gene. 2004 Mar 17;328:153-65.
  • Scheijen B, Ngo HT, Kang H, Griffin JD.FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins.Oncogene. 2004 Apr 22;23(19):3338-49.
  • Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG.Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3130-5.
  • Cools J, Quentmeier H, Huntly BJ, Marynen P, Griffin JD, Drexler HG, Gilliland DG.The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.Blood. 2004 Apr 1;103(7):2802-5.
  • Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, Griffin JD, Johnson BE, Salgia R.c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.Cancer Res. 2003 Oct 1;63(19):6272-81.
  • Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC.NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.Blood. 2003 Oct 1;102(7):2615-22.
  • Sattler M, Griffin JD.Molecular mechanisms of transformation by the BCR-ABL oncogene.Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10.
  • Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, Coutre SE, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, Gilliland DG.PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease.Cancer Cell. 2003 May;3(5):459-69.
  • Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, Cross NC, Tefferi A, Malone J, Alam R, Schrier SL, Schmid J, Rose M, Vandenberghe P, Verhoef G, Boogaerts M, Wlodarska I, Kantarjian H, Marynen P, Coutre SE, Stone R, Gilliland DG.A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.N Engl J Med. 2003 Mar 27;348(13):1201-14.
  • Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, Pieters R, Kersey JH, Sallan SE, Fletcher JA, Golub TR, Griffin JD, Korsmeyer SJ.Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.Cancer Cell. 2003 Feb;3(2):173-83.
  • Weng AP, Nam Y, Wolfe MS, Pear WS, Griffin JD, Blacklow SC, Aster JC.Growth suppression of pre-T acute lymphoblastic leukemia cells by inhibition of notch signaling.Mol Cell Biol. 2003 Jan;23(2):655-64.
  • Wu L, Sun T, Kobayashi K, Gao P, Griffin JD.Identification of a family of mastermind-like transcriptional coactivators for mammalian notch receptors.Mol Cell Biol. 2002 Nov;22(21):7688-700.
  • Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC.The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.Cancer Res. 2002 Sep 1;62(17):5019-26.
  • Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, Gilliland DG, Griffin JD.Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.Cancer Cell. 2002 Jun;1(5):433-43.
  • Sattler M, Mohi MG, Pride YB, Quinnan LR, Malouf NA, Podar K, Gesbert F, Iwasaki H, Li S, Van Etten RA, Gu H, Griffin JD, Neel BG.Critical role for Gab2 in transformation by BCR/ABL.Cancer Cell. 2002 Jun;1(5):479-92.
  • Gilliland DG, Griffin JD.Role of FLT3 in leukemia.Curr Opin Hematol. 2002 Jul;9(4):274-81.
  • Scheijen B, Griffin JD.Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease.Oncogene. 2002 May 13;21(21):3314-33.
  • Liu S, Kiosses WB, Rose DM, Slepak M, Salgia R, Griffin JD, Turner CE, Schwartz MA, Ginsberg MH.A fragment of paxillin binds the alpha 4 integrin cytoplasmic domain (tail) and selectively inhibits alpha 4-mediated cell migration.J Biol Chem. 2002 Jun 7;277(23):20887-94.
  • Lu Q, Mukhopadhyay NK, Griffin JD, Paredes M, Medina M, Kosik KS.Brain armadillo protein delta-catenin interacts with Abl tyrosine kinase and modulates cellular morphogenesis in response to growth factors.J Neurosci Res. 2002 Mar 1;67(5):618-24.
  • Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H, Salgia R, Lipkowitz S, Griffin JD.Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.Oncogene. 2002 Feb 21;21(9):1423-33.
  • Griffin JD.Resistance to targeted therapy in leukaemia.Lancet. 2002 Feb 9;359(9305):458-9.
  • Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH.Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.Blood. 2002 Jan 15;99(2):664-71.
  • Chai Y, Wu L, Griffin JD, Paulson HL.The role of protein composition in specifying nuclear inclusion formation in polyglutamine disease.J Biol Chem. 2001 Nov 30;276(48):44889-97.
  • Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, Fletcher JA, Demetri GD.STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.Oncogene. 2001 Aug 16;20(36):5054-8.
  • Bruecher-Encke B, Griffin JD, Neel BG, Lorenz U.Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation.Leukemia. 2001 Sep;15(9):1424-32.
  • Okuda K, Weisberg E, Gilliland DG, Griffin JD.ARG tyrosine kinase activity is inhibited by STI571.Blood. 2001 Apr 15;97(8):2440-8.
  • Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD.MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors.Nat Genet. 2000 Dec;26(4):484-9.
  • Varnum-Finney B, Wu L, Yu M, Brashem-Stein C, Staats S, Flowers D, Griffin JD, Bernstein ID.Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling.J Cell Sci. 2000 Dec;113 Pt 23:4313-8.
  • Sattler M, Verma S, Pride YB, Salgia R, Rohrschneider LR, Griffin JD.SHIP1, an SH2 domain containing polyinositol-5-phosphatase, regulates migration through two critical tyrosine residues and forms a novel signaling complex with DOK1 and CRKL.J Biol Chem. 2001 Jan 26;276(4):2451-8.
  • Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD.BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.J Biol Chem. 2000 Dec 15;275(50):39223-30.
  • Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R.Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.Oncogene. 2000 Jul 20;19(31):3521-8.
  • Sillaber C, Gesbert F, Frank DA, Sattler M, Griffin JD.STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells.Blood. 2000 Mar 15;95(6):2118-25.
  • Ichinohasama R, Miura I, Takahashi N, Sugawara T, Tamate E, Endoh K, Endoh F, Naganuma H, DeCoteau JF, Griffin JD, Kadin ME, Ooya K.Ph-negative non-Hodgkin's lymphoma occurring in chronic phase of Ph-positive chronic myelogenous leukemia is defined as a genetically different neoplasm from extramedullary localized blast crisis: report of two cases and review of the literature.Leukemia. 2000 Jan;14(1):169-82.
  • Shen Y, Lyons P, Cooley M, Davidson D, Veillette A, Salgia R, Griffin JD, Schaller MD.The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo.J Biol Chem. 2000 Jan 14;275(2):1405-13.
  • Salgia R, Quackenbush E, Lin J, Souchkova N, Sattler M, Ewaniuk DS, Klucher KM, Daley GQ, Kraeft SK, Sackstein R, Alyea EP, von Andrian UH, Chen LB, Gutierrez-Ramos JC, Pendergast AM, Griffin JD.The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha.Blood. 1999 Dec 15;94(12):4233-46.
  • Sattler M, Verma S, Byrne CH, Shrikhande G, Winkler T, Algate PA, Rohrschneider LR, Griffin JD.BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis.Mol Cell Biol. 1999 Nov;19(11):7473-80.
  • Uemura N, Salgia R, Ewaniuk DS, Little MT, Griffin JD.Involvement of the adapter protein CRKL in integrin-mediated adhesion.Oncogene. 1999 Jun 3;18(22):3343-53.
  • Sattler M, Winkler T, Verma S, Byrne CH, Shrikhande G, Salgia R, Griffin JD.Hematopoietic growth factors signal through the formation of reactive oxygen species.Blood. 1999 May 1;93(9):2928-35.
  • Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD, Sugarbaker DJ.Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.Oncogene. 1999 Jan 7;18(1):67-77.
  • Okuda K, D'Andrea A, Van Etten RA, Griffin JD.The C-terminus of c-ABL is required for proliferation and viability signaling in a c-ABL/erythropoietin receptor fusion protein.Blood. 1998 Nov 15;92(10):3848-56.
  • Tong X, Salgia R, Li JL, Griffin JD, Howley PM.The bovine papillomavirus E6 protein binds to the LD motif repeats of paxillin and blocks its interaction with vinculin and the focal adhesion kinase.J Biol Chem. 1997 Dec 26;272(52):33373-6.
  • Sattler M, Salgia R, Shrikhande G, Verma S, Choi JL, Rohrschneider LR, Griffin JD.The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors.Oncogene. 1997 Nov 6;15(19):2379-84.
  • Okuda K, D'Andrea A, Etten RA, Griffin JD.A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo.J Clin Invest. 1997 Oct 1;100(7):1708-15.
  • Salgia R, Li JL, Ewaniuk DS, Pear W, Pisick E, Burky SA, Ernst T, Sattler M, Chen LB, Griffin JD.BCR/ABL induces multiple abnormalities of cytoskeletal function.J Clin Invest. 1997 Jul 1;100(1):46-57.
  • Gu H, Griffin JD, Neel BG.Characterization of two SHP-2-associated binding proteins and potential substrates in hematopoietic cells.J Biol Chem. 1997 Jun 27;272(26):16421-30.
  • Sattler M, Salgia R, Shrikhande G, Verma S, Uemura N, Law SF, Golemis EA, Griffin JD.Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1).J Biol Chem. 1997 May 30;272(22):14320-6.
  • Inhorn RC, Carlesso N, Durstin M, Frank DA, Griffin JD.Identification of a viability domain in the granulocyte/macrophage colony-stimulating factor receptor beta-chain involving tyrosine-750.Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8665-9.
  • Quelle FW, Sato N, Witthuhn BA, Inhorn RC, Eder M, Miyajima A, Griffin JD, Ihle JN.JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region.Mol Cell Biol. 1994 Jul;14(7):4335-41.
  • Ando K, Ajchenbaum-Cymbalista F, Griffin JD.Regulation of G1/S transition by cyclins D2 and D3 in hematopoietic cells.Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9571-5.
  • Furukawa Y, DeCaprio JA, Belvin M, Griffin JD.Heterogeneous expression of the product of the retinoblastoma susceptibility gene in primary human leukemia cells.Oncogene. 1991 Aug;6(8):1343-6.
  • Spertini O, Freedman AS, Belvin MP, Penta AC, Griffin JD, Tedder TF.Regulation of leukocyte adhesion molecule-1 (TQ1, Leu-8) expression and shedding by normal and malignant cells.Leukemia. 1991 Apr;5(4):300-8.
  • Kanakura Y, Cannistra SA, Brown CB, Nakamura M, Seelig GF, Prosise WW, Hawkins JC, Kaushansky K, Griffin JD.Identification of functionally distinct domains of human granulocyte-macrophage colony-stimulating factor using monoclonal antibodies.Blood. 1991 Mar 1;77(5):1033-43.
  • Kanakura Y, Druker B, DiCarlo J, Cannistra SA, Griffin JD.Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line.J Biol Chem. 1991 Jan 5;266(1):490-5.
  • Furukawa Y, Piwnica-Worms H, Ernst TJ, Kanakura Y, Griffin JD.cdc2 gene expression at the G1 to S transition in human T lymphocytes.Science. 1990 Nov 9;250(4982):805-8.
  • Cannistra SA, Koenigsmann M, DiCarlo J, Groshek P, Griffin JD.Differentiation-associated expression of two functionally distinct classes of granulocyte-macrophage colony-stimulating factor receptors by human myeloid cells.J Biol Chem. 1990 Jul 25;265(21):12656-63.
  • Furukawa Y, DeCaprio JA, Freedman A, Kanakura Y, Nakamura M, Ernst TJ, Livingston DM, Griffin JD.Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and noncycling human hematopoietic cells.Proc Natl Acad Sci U S A. 1990 Apr;87(7):2770-4.
  • Cannistra SA, Groshek P, Garlick R, Miller J, Griffin JD.Regulation of surface expression of the granulocyte/macrophage colony-stimulating factor receptor in normal human myeloid cells.Proc Natl Acad Sci U S A. 1990 Jan;87(1):93-7.
  • DeCaprio JA, Ludlow JW, Lynch D, Furukawa Y, Griffin J, Piwnica-Worms H, Huang CM, Livingston DM.The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element.Cell. 1989 Sep 22;58(6):1085-95.